Myriad Genetics Outlines 2026 Revenue Guidance Following $210 Million Prenatal Health Divestiture
Myriad Genetics (MYGN) has provided a revenue outlook for 2026 in the range of $780 million to $790 million. This guidance follows the company's strategic decision to divest its Prenatal Health business in a deal valued at approximately $210 million. During the Q3 earnings call, management acknowledged several ongoing operational headwinds, including continued softness within the prenatal segment prior to divestiture, reimbursement pressures affecting Hereditary Cancer Testing (HCT), and general financial stability concerns. The company is implementing decisive actions to navigate these challenges and stabilize its long-term fiscal position.
Tickers: $MYGN
Topics: earnings call financial stability prenatal health reimbursement pressure
Read the full article at Seeking Alpha
Part of the story Myriad Genetics Reports Q3 2026 Results and Announces Prenatal Health Divestiture to Labcorp (4 articles)